DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in hela cells

Molecular Cancer Research

Volumn 8, Issue 11, 2010, Pages 1547-1557

  Watanabe, Masaru ^a   Naraba, Hiroaki ^a   Sakyo, Tomoko ^a   Kitagawa, Takayuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CAMPTOTHECIN; DOXORUBICIN; ETOPOSIDE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BUTADIENES; CACO-2 CELLS; CAMPTOTHECIN; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUCOSE TRANSPORTER TYPE 3; HELA CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

MAMMALIA;

EID: 78649644992     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0011     Document Type: Article

References (53)

1. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-7.
2. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
4. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
5. 18F]fluorodeoxyglucose: Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 1999;126:549-59.
6. 18F]fluoro-2-deoxy-D-glucose in oncology: Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000;126:560-74.
7. Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genomics 2007;8:113-28.
8. Keller K, Strube M, Mueckler M. Functional expression of the human HepG2 and rat adipocyte glucose transporters in Xenopus oocytes. Comparison of kinetic parameters. J Biol Chem 1989;264:18884-9. (Pubitemid 19285786)
9. Burant CF, Bell GI. Mammalian facilitative glucose transporters: Evidence for similar substrate recognition sites in functionally monomeric proteins. Biochemistry 1992;31:10414-20.
10. Boado RJ, Black KL, Pardridge WN. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res 1994;27:51-7.
11. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter GLUT1 in human cancers. Cancer Res 1996;56:1164-7.
12. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Immunohistochemical detection of GLUT3 in human tumors and normal tissues. Anticancer Res 1997;17:2747-50.
13. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of GLUT1 and GLUT3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51. (Pubitemid 27427603)
14. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-62. (Pubitemid 40175840)
15. Kim SJ, Lee HW, Kim DC, Rha SH, Hong SH, Jeong JS. Significance of GLUT1 expression in adenocarcinoma and adenoma of the ampulla of Vater. Pathol Int 2008;58:233-8.
16. Tsukioka M, Matsumoto Y, Noriyuki M, et al. Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol Rep 2007;18:361-7.
17. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter mRNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
18. Kitagawa T, Tanaka M, Akamatsu Y. Regulation of glucose transport activity and expression of glucose transporter mRNA by serum, growth factors and phorbol ester in quiescent mouse fibroblasts. Biochim Biophys Acta 1989;980:100-8.
19. Kitagawa T, Tsuruhara Y, Hayashi M, Endo T, Stanbridge EJ. A tumor-associated glycosylation change in the glucose transporter GLUT1 controlled by tumor suppressor function in human cell hybrids. J Cell Sci 1995;108:3735-43.
20. Noto Y, Iwazaki A, Nagao J, et al. Altered N-glycosylation of glucose transporter-1 associated with radiation-induced tumorigenesis of human cell hybrids. Biochem Biophys Res Commun 1997;240:395-8.
21. Suzuki T, Iwazaki A, Katagiri H, et al. Enhanced expression of glucose transporter GLUT3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction. Eur J Biochem 1999;262:534-40.
22. Rajakumar RA, Thamotharan S, Menon RK, Devaskar SU. Sp1 and Sp3 regulate transcriptional activity of the facilitative glucose transporter isoform-3 gene in mammalian neuroblasts and trophoblasts. J Biol Chem 1998;273:27474-83.
23. Rajakumar RA, Thamotharan S, Raychaudhuri N, Menon RK, Devaskar SU. Trans-activators regulating neuronal glucose transporter isoform-3 gene expression in mammalian neurons. J Biol Chem 2004;279:26768-79.
24. Copland JA, Pardini AW, Wood TG, et al. IGF-I controls GLUT3 expression in muscle via the transcriptional factor Sp1. Biochim Biophys Acta 2007;1769:631-40.
25. Meneses AM, Medina RA, Kato S, et al. Regulation of GLUT3 and glucose uptake by the cAMP signalling pathway in the breast cancer cell line ZR-75. J Cell Physiol 2008;214:110-6.
26. Zhou R, Vander Heiden MG, Rudin CM. Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res 2002;62:3515-20. (Pubitemid 34651402)
27. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006;12:440-50.
28. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009;9:714-23.
29. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006;10:501-14.
30. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nat Cell Biol 2008;10:611-8.
31. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79:329-39.
32. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000;19:5712-9.
33. Tang D, Wu D, Hirao A, et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002;277:12710-7.
34. Wu CY, Gómez-Curet I, Funanage VL, Scavina M, Wang W. Increased susceptibility of spinal muscular atrophy fibroblasts to camptothecin is p53-independent. BMC Cell Biol 2009;16:10-40.
35. Sakyo T, Kitagawa T. Differential localization of glucose transporter isoforms in non-polarized cells: distribution of GLUT1 but not GLUT3 to detergent-resistant membrane domain. Biochim Biophys Acta 2002;1567:165-75.
36. Stanbridge EJ, Flandermeyer RR, Daniels DW, Nelson-Rees WA. Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. Somatic Cell Genet 1981;7:699-712.
37. Stanbridge EJ, Der CJ, Doersen CJ, et al. Human cell hybrids: analysis of transformation and tumorigenicity. Science 1982;215:252-9.
38. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994;8:1235-46.
39. Sakyo T, Naraba H, Teraoka H, Kitagawa T. The intrinsic structure of glucose transporter isoforms GLUT1 and GLUT3 regulates their differential distribution to detergent-resistant membrane domains in nonpolarized mammalian cells. FEBS J 2007;274:2843-53. (Pubitemid 46800548)
40. Watanabe M, Fiji HD, Guo L, et al. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 2008;283:9571-9.
41. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004;64:2627-33.
42. Djelloul S, Forgue-Lafitte ME, Hermelin B, Mareel M, Bruyneel E, Baldi A, Giordano A, Chastre E, Gespach C. Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products. FEBS Lett 1997;406:234-42.
43. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
44. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338-50.
45. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009;9:691-700.
46. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009;9:501-7.
47. Roos WP, Batista LF, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2006;26:186-97.
48. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 1999;431:199-209.
49. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
50. Fan S, Meng Q, Laterra JJ, Rosen EM. Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem 2009;284:7561-77.
51. Vaughn AE, Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 2008;10:1477-83.
52. Schafer ZT, Grassian AR, Song L, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009;461:109-13.
53. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325:1555-9.